← Back to Search

Small Molecule Inhibitor

PLX2853 for Prostate Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by Opna-IO LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥18 years at the time of signing informed consent.
Histologically confirmed adenocarcinoma of the prostate with tumor tissue available for molecular analyses.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from time of first dose until completion of long term follow-up, approximately 30 months.
Awards & highlights

Study Summary

This study is evaluating whether a drug may help treat prostate cancer.

Eligible Conditions
  • Prostate Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from time of first dose until completion of long term follow-up, approximately 30 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and from time of first dose until completion of long term follow-up, approximately 30 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Therapeutic procedure
Phase 1b (both arms): Incidence of dose-limiting-toxicities (DLTs)
Disease
Secondary outcome measures
Upper arm
Upper arm
Duration of Response (DOR) (both arms, both phases)
+9 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: PLX2853 + OlaparibExperimental Treatment2 Interventions
Phase 1b (PLX2853 + Olaparib Combination): Up to 18 evaluable subjects with homologous recombination repair (HRR) gene-mutated mCRPC will be enrolled. Phase 2a (PLX2853 + Olaparib Combination): Up to 58 evaluable subjects with homologous recombination repair (HRR) gene-mutated mCRPC will be enrolled.
Group II: PLX2853 + Abiraterone Acetate + PrednisoneExperimental Treatment3 Interventions
Phase 1b (PLX2853 + Abiraterone Acetate + Prednisone Combination): Up to 15 evaluable subjects with mCRPC will be enrolled. Phase 2a (PLX2853 + Abiraterone Acetate + Prednisone Combination): Up to 19 evaluable subjects with mCRPC will be enrolled.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Abiraterone acetate
2014
Completed Phase 3
~3440
Olaparib
2007
Completed Phase 4
~2140
PLX2853
2019
Completed Phase 1
~80
Prednisone
2014
Completed Phase 4
~2370

Find a Location

Who is running the clinical trial?

Opna-IO LLCLead Sponsor
3 Previous Clinical Trials
108 Total Patients Enrolled
PlexxikonLead Sponsor
24 Previous Clinical Trials
1,082 Total Patients Enrolled
1 Trials studying Prostate Cancer
6 Patients Enrolled for Prostate Cancer

Frequently Asked Questions

~4 spots leftby Mar 2025